Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
Starting soon · Not applicable
Conditions studied: Diabetic Kidney Disease (DKD)
In brief
GOLD-STANDARD is a pragmatic, open-label pilot randomized controlled trial evaluating the feasibility and safety of early goal-directed Cardio-Kidney-Metabolic (CKM) care compared with usual care in patients with diabetic kidney disease. Participants will be randomized 1:1 and managed by nephrologists. The intervention includes structured kidney and cardiovascular risk assessment, early shared decision-making regarding guideline-directed medical therapies, and close monitoring for adverse effects. The usual care group will receive standard clinical management at the discretion of the treating clinician. The study will be conducted in Ontario using existing health care infrastructure.
Key facts
- Study ID
- NCT07434791
- Run by
- Sunnybrook Health Sciences Centre
- People needed
- 100
- Starts
- 2026-06-01
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2026-05-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years
- T2DM
- CKD (eGFR ≥ 25-60 OR UACR ≥ 30 mg/g)
- High Cardiovascular (CV) Risk: Defined as a history of prior myocardial infarction (MI), stroke, or peripheral artery disease (PAD), or the presence of cardiovascular risk factors, (specifically age 40 years or older and at least one of the following: cholesterol above target (LDL≥1.8 mmol/L OR on cholesterol lowering medication), hypertension (≥130/80 mmHg or on BPLMs), or atrial fibrillation.)
- Open to start new medications
You may not qualify if…
- Type 1 diabetes
- HbA1c ≥10% on screening labs
- Serum potassium ≥ 5.2 mmol/L on screening labs
- Baseline Blood Pressure (BP) < 100/60 mmHg at screening
- Treated with new or intensified immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days
- Kidney Transplant
- Use of ≥3 medication classes: Participants already prescribed three or more of the following classes of medications: RASi, SGLT2i, nsMRA or GLP1RA
- Intolerance or allergy to any of RASi, SGLT2i, nsMRA or GLP1RA
- Known Heart Failure with Reduced Ejection Fraction (HFrEF)
- Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.